Articles from Santa Ana Bio, Inc.

ALAMEDA, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Santa Ana Bio, a clinical-stage precision immunology company, today announced that preclinical data on SAB05, its CD40-targeted glucocorticoid antibody-drug conjugate (ADC), will be presented in a poster at ACR Convergence 2026, the annual meeting of the American College of Rheumatology (ACR), taking place November 6–11, 2026, in Orlando, Florida.

ALAMEDA, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, today announced that the first cohort has been dosed in the first-in-human Phase 1 study of SAB01, a novel bispecific antibody designed to selectively deplete mast cells through co-engagement of KIT and Siglec-6.

Santa Ana Bio, a precision immunology company developing targeted therapies for patients with autoimmune and inflammatory diseases, today emerged from stealth with $168 million in combined Series A and B funding. Founding investor Versant Ventures led the Series A round and was joined by TPG’s Life Science Innovations fund and GV. The $125 million Series B round was led by GV, with participation from all existing investors as well as new investors Access Biotechnology, Andreessen Horowitz (a16z) Bio + Health and RTW.